Collegium Pharmaceutical, Inc. COLL Xtampza ER — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s xtampza er — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s xtampza ER — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported xtampza ER — product revenues, net of $50.77M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s xtampza ER — product revenues, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s xtampza ER — product revenues, net increased by 6.6% year-over-year, from $47.64M to $50.77M.
- What does xtampza ER — product revenues, net mean?
- This metric represents the total net revenue generated from the sale of a specific pharmaceutical product after accounting for returns, discounts, rebates, and other sales allowances. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line financial performance. Tracking this figure allows investors to evaluate the growth trajectory and competitive positioning of the specific therapeutic asset within its respective market segment.